Q-omics provides the consensus-scored ARSFP1 profile across patient tissues and cancer cell-line models. ARSFP1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ARSFP1 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, ARSFP1 RNA expression shows 9,481 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRP, and TGCT as cancer lineages where ARSFP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARSFP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARSFP1 survival associations across molecular data types. ARSFP1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARSFP1 RNA expression–survival associations across cancer types. High ARSFP1 expression shows unfavorable associations in UCEC, SKCM, BRCA and PRAD, but favorable associations in HNSC and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for ARSFP1 RNA expression.
This table summarizes ARSFP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARSFP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARSFP1 shows lower tumor expression in KIRP, KIRC, HNSC, KICH, LUSC and ESCA. The KIRP box plot shows higher ARSFP1 RNA expression in normal versus tumor tissue (log2 FC = −0.744, t-test p < 0.001).
This table shows molecular features associated with ARSFP1 in patient tissues and cancer cell lines. In patient samples, ARSFP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
